Is Regeneron Pharmaceuticals, Inc. Stock a Buy?
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller-coaster ride, though, with the stock plunging in 2016 but bouncing back somewhat this year.
What Regeneron has done in the past isn't nearly as important to investors as what the biotech could do in the future. Is the stock now a buy? Here are the arguments for and against Regeneron.
Image source: Getty Images.
Source: Fool.com
Sanofi S.A. ADR Stock
Sanofi S.A. ADR is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
With a target price of 55 € there is a slightly positive potential of 14.11% for Sanofi S.A. ADR compared to the current price of 48.2 €.